Recent Company News

• 08:29 AM ET Dec 19, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 02:31 AM ET Dec 22, 2025
  

  AstraZeneca's Enhertu granted BTD for post-neoadjuvant early BC (13672.0000p, 0)

• 02:03 AM ET Dec 22, 2025
  

  AstraZeneca announces LATIFY Phase III trial of ceralasertib in combination with IMFINZI did not meet primary endpoint of overall survival versus standard-of-care docetaxel in patients with locally advanced or metastatic non-small cell lung cancer

• 07:32 AM ET Dec 21, 2025
  

  Jacobio Pharmaceuticals Group, AstraZeneca enter license and collaboration agreement for Pan-KRAS inhibitor JAB23E73. (HK$9.06, 0.00)

• 04:42 PM ET Dec 18, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:12 PM ET Dec 18, 2025
  

  FDA provides update on the safety of Andexxa; AstraZeneca will end sales next week ($90.61, 0.00)

• 02:40 AM ET Dec 18, 2025
  

  EMA accepts a partial variation application for Daiichi Sankyo's Dato-DXd/DS-1062 (¥3341.0000, 0)

• 07:08 AM ET Dec 17, 2025
  

  Compugen announces monetization of portion of rilvegostomig future royalties through amendment to license agreement with AstraZeneca (AZN.LN) ($1.49, 0.00)

• 02:10 AM ET Dec 16, 2025
  

  AstraZeneca PLC's Saphnelo approved in EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus (13612.0000p, 0)